XML 30 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Treasury Stock
Balance at beginning of period ( in shares) at Dec. 31, 2020   384.4        
Balance at beginning of period at Dec. 31, 2020 $ 1,551.9 $ 0.4 $ 1,726.5 $ 3.2 $ (78.2) $ (100.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   2.9        
Issuance of common stock under equity incentive plans 0.0          
Issuance of common stock for employee stock purchase plan (in shares)   0.3        
Issuance of common stock for Employee Stock Purchase Plan $ 20.3   20.3      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 0.0          
Tax benefit related to Senior Convertible Notes $ (2.0)   (2.0)      
Conversions of 2023 Notes (in shares) (0.8) 1.4        
Conversions of 2023 Notes $ 57.2   32.6     24.6
Benefit of note hedge upon conversions of 2023 Notes (in shares) (1.0) (1.0)        
Benefit of note hedge upon conversions of 2023 Notes $ 0.0   130.8     (130.8)
Share-based compensation expense 113.4   113.4      
Collaborative research and development fee 87.1   87.1      
Net income 216.9       216.9  
Other comprehensive income (loss), net of tax (2.7)     (2.7)    
Balance at end of period (in shares) at Dec. 31, 2021   388.0        
Balance at end of period at Dec. 31, 2021 2,042.1 $ 0.4 2,108.7 0.5 138.7 (206.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   1.6        
Issuance of common stock under equity incentive plans 0.0          
Issuance of common stock for employee stock purchase plan (in shares)   0.3        
Issuance of common stock for Employee Stock Purchase Plan $ 22.5   22.5      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 2.9 2.9        
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs $ (0.1)   (189.3)     189.2
Tax benefit related to Senior Convertible Notes $ (0.4)   (0.4)      
Conversions of 2023 Notes (in shares) (0.4) 0.4        
Conversions of 2023 Notes $ 17.4   4.2     13.2
Benefit of note hedge upon conversions of 2023 Notes (in shares) (0.3) (0.3)        
Benefit of note hedge upon conversions of 2023 Notes $ 0.0   33.5     (33.5)
Purchases of treasury stock (in shares)   (6.6)        
Purchases of treasury stock (557.7)         (557.7)
Share-based compensation expense 126.5   126.5      
Capitalization of sales-based milestones 152.4   152.4      
Net income 341.2       341.2  
Other comprehensive income (loss), net of tax $ (12.1)     (12.1)    
Balance at end of period (in shares) at Dec. 31, 2022 386.3 386.3        
Balance at end of period at Dec. 31, 2022 $ 2,131.8 $ 0.4 2,258.1 (11.6) 479.9 (595.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity incentive plans (in shares)   1.4        
Issuance of common stock under equity incentive plans 0.0          
Issuance of common stock for employee stock purchase plan (in shares)   0.3        
Issuance of common stock for Employee Stock Purchase Plan $ 26.6   26.6      
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs (in shares) 3.7 3.7        
Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs $ (0.2)   (323.4)     323.2
Tax benefit related to Senior Convertible Notes $ (4.4)   (4.4)      
Conversions of 2023 Notes (in shares) 0.0 12.2        
Conversions of 2023 Notes $ (13.1)   (13.1)      
Benefit of note hedge upon conversions of 2023 Notes (in shares) (12.2) (12.2)        
Benefit of note hedge upon conversions of 2023 Notes $ 6.2   1,496.5     (1,490.3)
Purchases of treasury stock (in shares)   (6.3)        
Purchases of treasury stock (689.2)   (0.2)     (689.0)
Purchase of capped call transactions, net of tax (76.3)   (76.3)      
Share-based compensation expense 150.8   150.8      
Net income 541.5       541.5  
Other comprehensive income (loss), net of tax $ (5.1)     (5.1)    
Balance at end of period (in shares) at Dec. 31, 2023 385.4 385.4        
Balance at end of period at Dec. 31, 2023 $ 2,068.6 $ 0.4 $ 3,514.6 $ (16.7) $ 1,021.4 $ (2,451.1)